Clinical trial · Interventional
Axillary Reverse Mapping in Breast Cancer
Axillary Reverse Mapping (ARM): Validation of Surgical Tecnique in Breast Cancer Surgery
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The axillary mapping reverse (ARM) consists in differentiating the upper limb lymph nodes from the breast ones in order to preserve them and reduce the possibility of lymphedema. A significant decrease of lymphedema rates in patients who was possible associate ARM technique during the axillary surgery improving the quality of life of these patients. There are different visualisation techniques like fluorescence dye.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymph Node Cancer Metastatic | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Axillary mapping reverse | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Axillary mapping reverse
- description
- Application of axillary mapping reverse technique
- interventionNames
- Procedure: Axillary mapping reverse
Primary outcomes (1)
- measure
- Rate of patients who it is possible preserve ARM nodes
- timeFrame
- 1 year
- description
- Determinate the percentage of patients who is possible preserve the ARM node during ALND
Secondary outcomes (1)
- measure
- Rate of metastatic ARM
- timeFrame
- 1 year
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: Patients who will undergo ALND in the treatment of breast cancer: * cT4a, cT4c and cT4d. * cT4b with extensive involvement of the skin. * cN0 with SLNB positive (pN+) that need to associate ALND: * cT3-T4b. * \>2 lymph node macrometastasis if cTis, cT1 and cT2. * Patients who underwent mastectomy and it is not possible associate adjuvant radiotherapy. * cN1: * If primary surgery treatment. * After neoadjuvant systemic treatment, if there is not a clinical-radiological complete response and/or SLNB positive (ypN+). * cN2: * If primary surgery treatment. * After neoadjuvant systemic treatment, if luminal tumours or there is not a clinical-radiological complete response in triple negative or HER2 overexpressed tumours. * cN3. Exclusion Criteria: * Patients with previous axillary surgery (except sentinel node biopsy) * Patients who did previous axillary radiotherapy treatment. * Patients who do not wish to participate in the study.
References
Publications (0)
Data not yet available